Biovica is uniquely positioned to address one of the major challenges in cancer therapy today; how to better evaluate therapeutic efficacy and improve quality of life in patients with advanced stages of the disease.

A simple blood sample

DiviTum™ is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. It offers several advantages over alternative techniques that are standard in advanced breast cancer. In several clinical trials, the DiviTum™ biomarker assay has demonstrated the potential to quickly evaluate treatment effect and accurately predict outcome using just a simple blood sample.

Read more about DiviTum

New unique data from US breast cancer congress

The results demonstrate that palbociclib significantly reduced serum TK-activity levels in patients with hormone sensitive, HER2- breast cancer already after 2 weeks of treatment. DiviTum™ measured changes in serum TK-activity that was significantly correlated to the tumor Ki67 proliferation index. DiviTum™ may thus serve as a non-invasive marker and early response indicator of the anti-tumor effect of CDK4/6 inhibitors like palbociclib.

Read more about the study

About Biovica

Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.

Read more about Biovica

Lund University includes DiviTum® in study for treatment efficacy evaluation of breast cancer patients

Lund University select Biovicas DiviTum® assay for inclusion in a study of 150 women with metastatic breast cancer. The purpose of the study is faster evaluation of treatment efficacy than current standard methods. Lund University will buy about 550 DiviTum tests.

Read More

Biovica participates in a European research project for developing a new cancer-drug

Biovica will participate in a EUROSTAR research project called SUBLYME, that will develop a new targeted drug for blood cancer. For Biovica the project expand the application of DiviTum® to one of the most common forms of blood cancer where the incidence has doubled in the past decades.

Read More

Biovica CEO Anders Rylander interviewed about AACR results

Biovica CEO Anders Rylander is interviewed by the results presented at the AACR conference 1-5 April 2017. Read the interview here.

Read More


from day one

Breast cancer

Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum™ biomarker assay, aim to increase survival and improve quality of life.

Read more about market need

Clinical trials and Collaborations

Biovica has successfully worked to realize its vision for Divitum™ by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).

Read more about clinical trials